SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Extended search

Träfflista för sökning "L773:2405 6316 srt2:(2021)"

Search: L773:2405 6316 > (2021)

  • Result 1-10 of 10
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Björeland, Ulrika, et al. (author)
  • Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy
  • 2021
  • In: Physics and Imaging in Radiation Oncology. - : Elsevier. - 2405-6316. ; 17, s. 117-123
  • Journal article (peer-reviewed)abstract
    • Background and purpose: In locally advanced prostate cancer (PC), androgen deprivation therapy (ADT) in combination with whole prostate radiotherapy (RT) is the standard treatment. ADT affects the prostate as well as the tumour on multiparametric magnetic resonance imaging (MRI) with decreased PC conspicuity and impaired localisation of the prostate lesion. Image texture analysis has been suggested to be of aid in separating tumour from normal tissue. The aim of the study was to investigate the impact of ADT on baseline defined MRI features in prostate cancer with the goal to investigate if it might be of use in radiotherapy planning.Materials and methods: Fifty PC patients were included. Multiparametric MRI was performed before, and three months after ADT. At baseline, a tumour volume was delineated on apparent diffusion coefficient (ADC) maps with suspected tumour content and a reference volume in normal prostatic tissue. These volumes were transferred to MRIs after ADT and were analysed with first-order -and invariant Haralick -features.Results: At baseline, the median value and several of the invariant Haralick features of ADC, showed a significant difference between tumour and reference volumes. After ADT, only ADC median value could significantly differentiate the two volumes.Conclusions: Invariant Haralick -features could not distinguish between baseline MRI defined PC and normal tissue after ADT. First-order median value remained significantly different in tumour and reference volumes after ADT, but the difference was less pronounced than before ADT.
  •  
2.
  • Byskov, Camilla S., et al. (author)
  • Treatment plan comparison of proton vs photon radiotherapy for lower-grade gliomas
  • 2021
  • In: Physics and Imaging in Radiation Oncology. - : Elsevier. - 2405-6316. ; 20, s. 98-104
  • Journal article (peer-reviewed)abstract
    • Background and purpose: Patients with lower-grade gliomas are long-term survivors after radiotherapy and may benefit from the reduced dose to normal tissue achievable with proton therapy. Here, we aimed to quantify differences in dose to the uninvolved brain and contralateral hippocampus and compare the risk of radiation-induced secondary cancer for photon and proton plans for lower-grade glioma patients. Materials and methods: Twenty-three patients were included in this in-silico planning comparative study and had photon and proton plans calculated (50.4 Gy(RBE = 1.1), 28 Fx) applying similar dose constraints to the target and organs at risk. Automatically calculated photon plans were generated with a 3 mm margin from clinical target volume (CTV) to planning target volume. Manual proton plans were generated using robust optimisation on the CTV. Dose metrics of organs at risk were compared using population mean dose-volume histograms and Wilcoxon signed-rank test. Secondary cancer risk per 10,000 persons per year (PPY) was estimated using dose-volume data and a risk model for secondary cancer induction. Results: CTV coverage (V95%>98%) was similar for the two treatment modalities. Mean dose (D-mean) to the uninvolved brain was significantly reduced from 21.5 Gy (median, IQR 17.1-24.4 Gy) with photons compared to 10.3 Gy(RBE) (8.1-13.9 Gy(RBE)) with protons. D-mean to the contralateral hippocampus was significantly reduced from 6.5 Gy (5.4-11.7 Gy) with photons to 1.5 Gy(RBE) (0.4-6.8 Gy(RBE)) with protons. The estimated secondary cancer risk was reduced from 6.7 PPY (median, range 3.3-10.4 PPY) with photons to 3.0 PPY (1.3-7.5 PPY) with protons. Conclusion: A significant reduction in mean dose to uninvolved brain and contralateral hippocampus was found with proton planning. The estimated secondary cancer risk was reduced with proton therapy.
  •  
3.
  • Fransson, Samuel, et al. (author)
  • Intrafractional motion models based on principal components in Magnetic Resonance guided prostate radiotherapy
  • 2021
  • In: Physics and Imaging in Radiation Oncology. - : Elsevier. - 2405-6316. ; 20, s. 17-22
  • Journal article (peer-reviewed)abstract
    • Background and purpose: Devices that combine an MR-scanner with a Linac for radiotherapy, referred to as MR-Linac systems, introduce the possibility to acquire high resolution images prior and during treatment. Hence, there is a possibility to acquire individualised learning sets for motion models for each fraction and the construction of intrafractional motion models. We investigated the feasibility for a principal component analysis (PCA) based, intrafractional motion model of the male pelvic region.Materials and methods: 4D-scans of nine healthy male volunteers were utilized, FOV covering the entire pelvic region including prostate, bladder and rectum with manual segmentation of each organ at each time frame. Deformable image registration with an optical flow algorithm was performed for each subject with the first time frame as reference. PCA was performed on a subset of the resulting displacement vector fields to construct individualised motion models evaluated on the remaining fields.Results: The registration algorithm produced accurate registration result, in general DICE overlap >0.95 across all time frames. Cumulative variance of the eigen values from the PCA showed that 50% or more of the motion is explained in the first component for all subjects. However, the size and direction for the components differed between subjects. Adding more than two components did not improve the accuracy significantly and the model was able to explain motion down to about 1 mm.onclusions: An individualised intrafractional male pelvic motion model is feasible. Geometric accuracy was about 1 mm based on 1-2 principal components.
  •  
4.
  • Götstedt, Julia, et al. (author)
  • Edge area metric complexity scoring of volumetric modulated arc therapy plans
  • 2021
  • In: Physics & Imaging in Radiation Oncology. - : Elsevier BV. - 2405-6316. ; 17, s. 124-129
  • Journal article (peer-reviewed)abstract
    • Background and purpose: Aperture-based complexity metrics have been suggested as a method to score complexity of volumetric modulated arc therapy (VMAT) plans. The purpose of this study was to evaluate the edge area metric (EAM) for clinical VMAT plans on a control point and treatment plan level. Materials and methods: EAM on a control point level was evaluated based on film measurements of 18 static beam openings originating from VMAT plans. EAM on a treatment plan level (arithmetic mean value of EAM scores for control points) was evaluated based on measurements with the Delta(4)(R) for 200 VMAT plans for four different treatment sites: pelvic, thorax, head and neck, and prostate. Measurements were compared to calculations and dose difference and gamma pass rates were evaluated. Results: EAM scores on a control point level correlated with Pearson's r-values of -0.96 and -0.77 to dose difference and gamma pass rates, respectively. The prostate plans had the highest average EAM score. A connection between smaller PTVs and higher EAM scores was found. No correlation between the evaluation result and EAM on a plan level was found. Conclusions: EAM on a control point level was shown to correlate to the difference between measured and calculated 2D dose distributions of clinical VMAT beam openings. No correlation was found for EAM on a plan level for clinical treatment plans.
  •  
5.
  • Jóhannesson, Vilberg, et al. (author)
  • Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer
  • 2021
  • In: Physics and imaging in radiation oncology. - : Elsevier BV. - 2405-6316. ; 18, s. 5-10
  • Journal article (peer-reviewed)abstract
    • Background: Treatment adaptation based on tumour biomarker response during radiotherapy of prostate cancer, could be used for both escalation and de-escalation of radiation doses and volumes. To execute an adaptation involving extension of treatment volumes during radiation can however be restricted by the doses already delivered. The aim of this work was to develop a treatment planning method that addresses this challenge. Material and methods: A volumetric-modulated-arc-therapy (VMAT) planning method with sequential plan-on-plan optimization was developed for a prospective phase II trial including 100 patients on salvage radiotherapy (SRT) for prostate cancer recurrence. A treatment adaptation was performed after five weeks of SRT based on prostate-specific antigen response during this phase of the treatment. This involved extension of treatment volumes for non-responders (n = 64) to include pelvic lymph nodes and boost to 68Gallium-Prostate-Specific-Membrane-Antigen-Positron-Emission-Tomography positive lesions. This method was evolved by introducing an EQD2 (equivalent dose in 2.0 Gy fractions) correction of the base plan for improved dose coverage. Results: All dose-volume criteria for target coverage were met for the non-responders when based on physical dose. An EQD2 correction of the base plan for non-responders, implemented for the final 29 patients, led to a statistically significant improvement in dose coverage as compared to the 35 patients treated without EQD2 correction. Conclusions: This is to our knowledge the only study presented on biomarker-guided sequential VMAT radiotherapy using a plan-on-plan technique in the pelvis. By using a biologically adapted technique an improved target coverage was achieved without compromising doses to organs at risk.
  •  
6.
  • Lazzeroni, Marta, et al. (author)
  • Evolution of the hypoxic compartment on sequential oxygen partial pressure maps during radiochemotherapy in advanced head and neck cancer
  • 2021
  • In: Physics and Imaging in Radiation Oncology. - : Elsevier BV. - 2405-6316. ; 17, s. 100-105
  • Journal article (peer-reviewed)abstract
    • Background and purposeLongitudinal Positron Emission Tomography (PET) with hypoxia-specific radiotracers allows monitoring the time evolution of regions of increased radioresistance and may become fundamental in determining the radiochemotherapy outcome in Head-and-Neck Squamous Cell Carcinoma (HNSCC). The aim of this study was to investigate the evolution of the hypoxic target volume on oxygen partial pressure maps (pO2-HTV) derived from 18FMISO-PET images acquired before and during radiochemotherapy and to uncover correlations between extent and severity of hypoxia and treatment outcome.Material and methods18FMISO-PET/CT images were acquired at three time points (before treatment start, in weeks two and five) for twenty-eight HNSCC patients treated with radiochemotherapy. The images were converted into pO2 maps and corresponding pO2-HTVs (pO2-HTV1, pO2-HTV2, pO2-HTV3) were contoured at 10 mmHg. Different parameters describing the pO2-HTV time evolution were considered, such as the percent and absolute difference between the pO2-HTVs (%HTVi,j and HTVi-HTVj with i,j = 1, 2, 3, respectively) and the slope of the linear regression curve fitting the pO2-HTVs in time. Correlations were sought between the pO2-HTV evolution parameters and loco-regional recurrence (LRR) using the Receiver Operating Characteristic method.ResultsThe Area Under the Curve values for %HTV1,2, HTV1-HTV2, HTV1-HTV3 and the slope of the pO2-HTV linear regression curve were 0.75 (p = 0.04), 0.73 (p = 0.02), 0.73 (p = 0.02) and 0.75 (p = 0.007), respectively. Other parameter combinations were not statistically significant.ConclusionsThe pO2-HTV evolution during radiochemotherapy showed predictive value for LRR. The changes in the tumour hypoxia during the first two treatment weeks may be used for adaptive personalized treatment approaches.
  •  
7.
  • Lempart, Michael, et al. (author)
  • Volumetric modulated arc therapy dose prediction and deliverable treatment plan generation for prostate cancer patients using a densely connected deep learning model
  • 2021
  • In: Physics and imaging in radiation oncology. - : Elsevier BV. - 2405-6316. ; 19, s. 112-119
  • Journal article (peer-reviewed)abstract
    • Background and purpose: Radiation therapy treatment planning is a manual, time-consuming task that might be accelerated using machine learning algorithms. In this study, we aimed to evaluate if a triplet-based deep learning model can predict volumetric modulated arc therapy (VMAT) dose distributions for prostate cancer patients. Materials and methods: A modified U-Net was trained on triplets, a combination of three consecutive image slices and corresponding segmentations, from 160 patients, and compared to a baseline U-Net. Dose predictions from 17 test patients were transformed into deliverable treatment plans using a novel planning workflow. Results: The model achieved a mean absolute dose error of 1.3%, 1.9%, 1.0% and ≤ 2.6% for clinical target volume (CTV) CTV_D100%, planning target volume (PTV) PTV_D98%, PTV_D95% and organs at risk (OAR) respectively, when compared to the clinical ground truth (GT) dose distributions. All predicted distributions were successfully transformed into deliverable treatment plans and tested on a phantom, resulting in a passing rate of 100% (global gamma, 3%, 2 mm, 15% cutoff). The dose difference between deliverable treatment plans and GT dose distributions was within 4.4%. The difference between the baseline model and our improved model was statistically significant (p < 0.05) for CVT_D100%, PTV_D98% and PTV_D95%. Conclusion: Triplet-based training improved VMAT dose distribution predictions when compared to 2D. Dose predictions were successfully transformed into deliverable treatment plans using our proposed treatment planning procedure. Our method may automate parts of the workflow for external beam prostate radiation therapy and improve the overall treatment speed and plan quality.
  •  
8.
  • Palmér, Emilia, 1993, et al. (author)
  • Synthetic computed tomography data allows for accurate absorbed dose calculations in a magnetic resonance imaging only workflow for head and neck radiotherapy
  • 2021
  • In: Physics and Imaging in Radiation Oncology. - : Elsevier BV. - 2405-6316. ; 17, s. 36-42
  • Journal article (peer-reviewed)abstract
    • Background and purpose: Few studies on magnetic resonance imaging (MRI) only head and neck radiation treatment planning exist, and none using a generally available software. The aim of this study was to evaluate the accuracy of absorbed dose for head and neck synthetic computed tomography data (sCT) generated by a commercial convolutional neural network-based algorithm. Materials and methods: For 44 head and neck cancer patients, sCT were generated and the geometry was validated against computed tomography data (CT). The clinical CT based treatment plan was transferred to the sCT and recalculated without re-optimization, and differences in relative absorbed dose were determined for dose-volume-histogram (DVH) parameters and the 3D volume. Results: For overall body, the results of the geometric validation were (Mean ± 1sd): Mean error −5 ± 10 HU, mean absolute error 67 ± 14 HU, Dice similarity coefficient 0.98 ± 0.05, and Hausdorff distance difference 4.2 ± 1.7 mm. Water equivalent depth difference for region Th1-C7, mid mandible and mid nose were −0.3 ± 3.4, 1.1 ± 2.0 and 0.7 ± 3.8 mm respectively. The maximum mean deviation in absorbed dose for all DVH parameters was 0.30% (0.12 Gy). The absorbed doses were considered equivalent (p-value < 0.001) and the mean 3D gamma passing rate was 99.4 (range: 95.7–99.9%). Conclusions: The convolutional neural network-based algorithm generates sCT which allows for accurate absorbed dose calculations for MRI-only head and neck radiation treatment planning. The sCT allows for statistically equivalent absorbed dose calculations compared to CT based radiotherapy.
  •  
9.
  • Sandgren, Kristina, et al. (author)
  • Registration of histopathology to magnetic resonance imaging of prostate cancer
  • 2021
  • In: Physics and Imaging in Radiation Oncology. - : Elsevier. - 2405-6316. ; 18, s. 19-25
  • Journal article (peer-reviewed)abstract
    • Background and purpose: The diagnostic accuracy of new imaging techniques requires validation, preferably by histopathological verification. The aim of this study was to develop and present a registration procedure between histopathology and in-vivo magnetic resonance imaging (MRI) of the prostate, to estimate its uncertainty and to evaluate the benefit of adding a contour-correcting registration.Materials and methods: For twenty-five prostate cancer patients, planned for radical prostatectomy, a 3D-printed prostate mold based on in-vivo MRI was created and an ex-vivo MRI of the specimen, placed inside the mold, was performed. Each histopathology slice was registered to its corresponding ex-vivo MRI slice using a 2D-affine registration. The ex-vivo MRI was rigidly registered to the in-vivo MRI and the resulting transform was applied to the histopathology stack. A 2D deformable registration was used to correct for specimen distortion concerning the specimen's fit inside the mold. We estimated the spatial uncertainty by comparing positions of landmarks in the in-vivo MRI and the corresponding registered histopathology stack.Results: Eighty-four landmarks were identified, located in the urethra (62%), prostatic cysts (33%), and the ejaculatory ducts (5%). The median number of landmarks was 3 per patient. We showed a median in-plane error of 1.8 mm before and 1.7 mm after the contour-correcting deformable registration. In patients with extraprostatic margins, the median in-plane error improved from 2.1 mm to 1.8 mm after the contour-correcting deformable registration.Conclusions: Our registration procedure accurately registers histopathology to in-vivo MRI, with low uncertainty. The contour-correcting registration was beneficial in patients with extraprostatic surgical margins.
  •  
10.
  • Vijande, Javier, et al. (author)
  • Source strength determination in iridium-192 and cobalt-60 brachytherapy : A European survey on the level of agreement between clinical measurements and manufacturer certificates
  • 2021
  • In: Physics and Imaging in Radiation Oncology. - : Elsevier. - 2405-6316. ; 19, s. 108-111
  • Journal article (peer-reviewed)abstract
    • Background and purpose: Brachytherapy treatment outcomes depend on the accuracy of the delivered dose distribution, which is proportional to the reference air-kerma rate (RAKR). Current societal recommendations require the medical physicist to compare the measured RAKR values to the manufacturer source calibration certificate. The purpose of this work was to report agreement observed in current clinical practice in the European Union. Materials and methods: A European survey was performed for high- and pulsed-dose-rate (HDR and PDR) highenergy sources (Ir-192 and Co-60), to quantify observed RAKR differences. Medical physicists at eighteen hospitals from eight European countries were contacted, providing 1,032 data points from 2001 to 2020. Results: Over the survey period, 77% of the Ir-192 measurements used a well chamber instead of the older Krieger phantom method. Mean differences with the manufacturer calibration certificate were 0.01% +/- 1.15% for Ir-192 and -0.1% +/- 1.3% for Co-60. Over 95% of RAKR measurements in the clinic were within 3% of the manufacturer calibration certificate. Conclusions: This study showed that the agreement level was generally better than that reflected in prior societal recommendations positing 5%. Future recommendations on high-energy HDR and PDR source calibrations in the clinic may consider tightened agreements levels.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 10
Type of publication
journal article (10)
Type of content
peer-reviewed (10)
Author/Editor
Nyholm, Tufve (3)
Bäck, Sven (2)
Strandberg, Sara, 19 ... (2)
Riklund, Katrine, MD ... (2)
Thellenberg-Karlsson ... (2)
Blomqvist, Lennart (2)
show more...
Jonsson, Joakim, 198 ... (2)
Wieslander, Elinore (1)
Munck af Rosenschöld ... (1)
Lempart, Michael (1)
Nordström, Fredrik, ... (1)
Bergh, Anders (1)
Söderström, Karin (1)
Carlsson Tedgren, Ås ... (1)
Ahlgren, Göran (1)
Widmark, Anders (1)
Kjellén, Elisabeth (1)
Nilsson, Per (1)
Brun, Eva (1)
Olsson, Tomas (1)
Axelsson, Jan, 1966- (1)
Karlsson, Anna (1)
Strand, Robin, 1978- (1)
Ahnesjö, Anders, 195 ... (1)
Nilsson, Mikael (1)
Lassen-Ramshad, Yasm ... (1)
Toma-Daşu, Iuliana (1)
Olsson, Lars E (1)
Nilsson, Erik (1)
Ljungberg, Maria (1)
Beckman, Lars (1)
Ögren, Margareta (1)
Lazzeroni, Marta (1)
Back, A. (1)
Götstedt, Julia (1)
Bitzén, Ulrika (1)
Ballester, Facundo (1)
Papagiannis, Panagio ... (1)
Rivard, Mark J. (1)
Siebert, Frank-Andre (1)
Vijande, Javier (1)
Ureba, Ana (1)
Benedek, Hunor (1)
Gunnlaugsson, Adalst ... (1)
Skorpil, Mikael (1)
Tilly, David, 1974- (1)
Hansen, Christian R. (1)
Björeland, Ulrika (1)
Witt Nyström, Petra (1)
Jamtheim Gustafsson, ... (1)
show less...
University
Karolinska Institutet (4)
Umeå University (3)
Lund University (3)
University of Gothenburg (2)
Uppsala University (2)
Stockholm University (1)
show more...
Linköping University (1)
show less...
Language
English (10)
Research subject (UKÄ/SCB)
Medical and Health Sciences (10)
Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view